1. |
Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J]. BMC Cancer, 2012, 12:263.
|
2. |
Murata S, Mine T, Ueda T, et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma[J]. Scientific World J, 2013, 2013:479805.
|
3. |
Varga M, Valsamis A, Matia I, et al. Transarterial chemoembolization in hepatocellular carcinoma[J]. Rozhl Chir, 2009, 88(8):434-438.
|
4. |
Biolato M, Marrone G, Racco S, et al. Transarterial chemoembolization (TACE) for unresectable HCC:a new life begins?[J]. Eur Rev Med Pharmacol Sci, 2010, 14(4):356-362.
|
5. |
Duan F, Wang MQ, Liu FY, et al. Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis[J]. Asia Pac J Clin Oncol, 2012, 8(2):156-163.
|
6. |
Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology, 2008, 48(4):1312-1327.
|
7. |
Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma[J]. Biologics, 2008, 2(4):779-788.
|
8. |
Personeni N, Rimassa L, Pressiani T, et al. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2013, 139(7):1179-1187.
|
9. |
Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J]. Semin Oncol, 2012, 39(4):493-502.
|
10. |
Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma[J]. Semin Oncol, 2012, 39(4):486-492.
|
11. |
Zhang X, Yang XR, Huang XW, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review[J]. Hepatobiliary Pancreat Dis Int, 2012, 11(5):458-466.
|
12. |
Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma:a meta-analysis of randomized trials[J]. Anticancer Drugs, 2010, 21(3):326-332.
|
13. |
Connock M, Round J, Bayliss S, et al. Sorafenib for the treatment of advanced hepatocellular carcinoma[J]. Health Technol Assess, 2010, 14 Suppl 1:17-21.
|
14. |
Abdel-Rahman O, Elsayed ZA. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma:a systematic review of the literature[J]. Dig Dis Sci, 2013, 58(12):3389-3396.
|
15. |
Shen A, Tang C, Wang Y, et al. A systematic review of sorafenib in child-pugh a patients with unresectable hepatocellular carcinoma[J]. J Clin Gastroenterol, 2013, 47(10):871-880.
|
16. |
Trojniak MP, Palozzo AC, Mazurek M, et al. Sorafenib in hepatocellular carcinoma-a post marketing evaluation[J]. Immunopharmacol Immunotoxicol, 2012, 34(3):419-422.
|
17. |
Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma[J]. Oncology, 2013, 84(2):108-114.
|
18. |
胡安斌, 何晓顺, 邰强, 等.索拉非尼在预防和治疗肝癌肝移植术后肿瘤复发中的疗效评价[J].中华医学杂志, 2012, 92(18):1264-1267.
|
19. |
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sora-fenib in patients with advanced hepatocellular carcinoma:subanal-yses of a phaseⅢtrial[J]. J Hepatol, 2012, 57(4):821-829.
|
20. |
Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status[J]. J Oncol Pract, 2014, 10(5):e335-e341.
|
21. |
Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines:10.Considering resource use and rating the quality of economic evidence[J]. J Clin Epidemiol, 2013, 66(2):140-150.
|
22. |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
|
23. |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
|
24. |
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J]. JAMA, 2010, 304(19):2154-2160.
|
25. |
Kudo M, Imanaka K, Chida N, et al. PhaseⅢstudy of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(14):2117-2127.
|
26. |
Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma:a propensity score matching study[J]. J Dig Dis, 2013, 14(4):181-190.
|
27. |
曾宪涛, 冷卫东, 李胜, 等.如何正确理解及使用GRADE系统[J].中国循证医学杂志, 2011, 11(9):985-990.
|
28. |
皋文君, 刘砚燕, 袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤, 2012, 32(2):142-144.
|
29. |
张岚, 任正刚.索拉菲尼治疗肝癌常见不良反应及处理的研究进展[J].中国肿瘤临床, 2013, 40(20):1268-1271.
|